Institutional members access full text with Ovid®

Share this article on:

A New Treatment for Pulmonary Arterial Hypertension

Aschenbrenner, Diane S. MS, RN

AJN The American Journal of Nursing: April 2016 - Volume 116 - Issue 4 - p 21
doi: 10.1097/01.NAJ.0000482134.59059.30
Drug Watch
  • A new orphan drug, selexipag (Uptravi), has been approved to treat pulmonary arterial hypertension. It promotes blood vessel dilation, delaying disease progression and reducing the risk of hospitalization.
  • In a clinical trial, the most common adverse effects were headache, diarrhea, jaw pain, nausea, myalgia, vomiting, pain in the extremities, flushing, arthralgia, anemia, and diminished appetite. Nausea can be minimized if the drug is taken with food.

Diane S. Aschenbrenner is an assistant professor at Notre Dame of Maryland University in Baltimore. She also coordinates Drug Watch: diane.aschenbrenner@ndm.edu.

Copyright © 2016 Wolters Kluwer Health, Inc. All rights reserved.